<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2406">
  <stage>Registered</stage>
  <submitdate>23/06/2009</submitdate>
  <approvaldate>23/06/2009</approvaldate>
  <nctid>NCT00927004</nctid>
  <trial_identification>
    <studytitle>Efficacy of Etoricoxib 60 mg in Modifying Pain Hypersensitivity in People With Knee Osteoarthritis</studytitle>
    <scientifictitle>A Randomised Placebo-controlled Trail of Mechanical and Cold Hyperalgesia in Subjects With Painful Knee Osteoarthritis, Compared With Matched Controls, &amp; Whether This Hyperalgesia Can be Modified by a 2-week Course of Etoricoxib 60mg.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>3144 Wright-Merck</secondaryid>
    <secondaryid>Moss IISP#36409</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Osteoarthritis</healthcondition>
    <healthcondition>Pain</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Osteoarthritis</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Etoricoxib (Arcoxia)
Treatment: drugs - Sugar pill

Experimental: Etoricoxib 60 mg - 

Placebo Comparator: Sugar pill - 


Treatment: drugs: Etoricoxib (Arcoxia)
60 mg, daily dose, oral delivery, 14 days duration

Treatment: drugs: Sugar pill
Daily dose (1 pill), oral delivery, 14 days

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Pressure Pain Threshold</outcome>
      <timepoint>15 days, 3 days</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Western Ontario and McMaster University Osteoarthritis Index (knee) - pain subscale</outcome>
      <timepoint>15 days, 3 days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Cold Pain Threshold</outcome>
      <timepoint>15 days, 3 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Topical Cold Response</outcome>
      <timepoint>15 days, 3 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Functional Measure (aggregated locomotor score, sit-to-stand time)</outcome>
      <timepoint>15 days, 3 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>WOMAC (knee) total</outcome>
      <timepoint>15 days, 3 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>SF-36v2</outcome>
      <timepoint>15 days, 3 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pain Quality Assessment Scale</outcome>
      <timepoint>15 days, 3 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PainDETECT questionnaire</outcome>
      <timepoint>15 days, 3 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  unilateral diagnosis of Knee OA &gt; 6 months

          -  knee pain &gt; 4/10 on WOMAC pain subscale

          -  if pain in contralateral knee, no greater than "mild"

          -  no other significant joint involvement

          -  ARA functional Class I, II or III

          -  no arthroscopy or injections into index knee in last 6 months</inclusivecriteria>
    <inclusiveminage>50</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  history of systemic inflammatory or chronic pain disorders (especially fibromyalgia)

          -  neurological deficit

          -  recent (&lt; 6 months) lower limb surgery

          -  allergic reaction to NSAIDs or aspirin

          -  skin allergies, dermatitis

          -  contraindications to Cox-2 inhibitors:

               -  congestive heart failure (NYHA II-IV)

               -  unstable hypertension

               -  ischaemic heart disease

               -  peripheral artery disease

               -  cerebrovascular disease including CABG or angioplasty within 1 year

          -  severe hepatic dysfunction

          -  active GI bleeding or peptic ulceration

          -  reduced creatinine clearance &lt; 30 mL/min

          -  current use of high dose (&gt; 325 mg daily) aspirin</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/08/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>80</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/12/2011</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>WA</recruitmentstate>
    <hospital>Royal Perth Hospital - Perth</hospital>
    <postcode>6000 - Perth</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Curtin University</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Merck Sharp &amp; Dohme Corp.</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study aims to better understand the way in which painful osteoarthritis affects
      different people and whether an anti-inflammatory medication such as Arcoxia (etoricoxib) can
      help to modify this pain. The study will use questionnaires and tests of pain sensitivity to
      identify arthritis sufferers with more widespread, nerve-type pain and then to investigate
      whether a daily dose of Arcoxia is more effective than a placebo pill in reducing these
      symptoms and improving functional movements. The study will also be comparing the same test
      results of a small group of subjects without knee pain.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00927004</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Tony Wright, PhD</name>
      <address>Curtin University</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>